Caprius, Inc. Announces Record Sales of SteriMed Systems and Increased Revenues for the Second Quarter

2008-05-14 23:36:58 -

www.caprius.com - Caprius, Inc. Beverly Tkaczenko, 201-342-0900, ext. 307 beverlyt@caprius.com or Barry Kaplan Associates Andrew Kaplan, 732-747-0702 smallkap@aol.com Caprius, Inc. (OTCBB: CAPS) announced that its subsidiary, MCM Environmental Technologies, Inc. ("MCM"), sold a record number of its SteriMed Systems to dialysis centers and hospitals during the second quarter of fiscal 2008.

Caprius also announced revenues for the second quarter ended March 31, 2008 (as reported in the Company's 10-QSB) of $1,095,017 as compared to $639,597 for the second quarter last year, reflecting an increase of 71.2%. For the six month period ended March 31, 2008, the total revenues were $1,788,673 as compared to $1,148,021 for the same period during fiscal 2007. This represents revenue growth of approximately 55.8%.

Dwight Morgan, Caprius' CEO and President, commented, "This is the first quarter in which MCM sales exceeded $1 million. This growth in sales reflects a combination of both repeat sales from existing customers as well as sales to new customers both domestically and internationally in high costs medical markets like Texas, Florida and the United Kingdom. Within the domestic market, the Company made its first sales in the states of Louisiana, North Carolina and Hawaii. These sales reflect the interest in our SteriMed Systems due to the continuously increasing costs of disposing of infectious medical waste."

Caprius is also pleased to also announce that it has retained Barry Kaplan Associates ("Kaplan"), of Fair Haven, New Jersey, to provide investor relations and corporate communications within the financial marketplace. Kaplan's objectives will be to expand the knowledge of Caprius in the financial marketplace by reaching key, innovative brokers, analysts, money managers, brokerage houses and institutions with the Company's activities and through exposure in the financial press.

Kaplan is a full-service investor relations firm that specializes in working with clients to effectively position them with current and prospective investors. Over the past 25 years, Kaplan has developed and executed investor relations programs that have proven to be very successful for public companies in gaining increased awareness in the financial marketplace in the United States, Canada and the UK.

Barry Kaplan, President of Barry Kaplan Associates, stated, "We are pleased to work with such a fine organization. The Company is showing strong growth in a rapidly growing and increasingly regulated worldwide market. The timing is perfect to proactively seek additional sponsorship from the financial community."

Mr. Morgan continued, "Additionally, we look forward to working with Kaplan to broaden our exposure in financial circles so that we can build our shareholder value to reflect the strong growth that our Company is experiencing."

About Caprius

Caprius, Inc. is a manufacturer of proprietary equipment for the on-site disinfection of infectious medical waste through its subsidiary, M.C.M. Environmental Technologies, Inc. The Company's innovative SteriMed technology simultaneously shreds and disinfects solid and liquid regulated medical waste, reducing the volume by up to 90% and rendering it harmless for disposal as ordinary waste. The SteriMed units are economical, compact, efficient and convenient, as well as environmentally friendly. The MCM patented technology offers an alternative to hauling and incinerating medical waste. Industry analysts estimate the medical waste market to be approximately $3 billion in the U.S. and approximately $10 billion worldwide. More information on the Company and MCM can be found at www.caprius.com and www.mcmetech.com.

Safe Harbor Statement

This press release may contain forward-looking statements that involve risks and uncertainties. These statements refer to future plans, objectives, expectations and intentions. These statements may be identified by the use of words such as "anticipate," "believe," "intend," "plan," "expect" and other similar expressions. The Company's actual results could differ materially from those discussed in, or implied by, such forward-looking statements. You should also be aware of risks and uncertainties that, in the Company's view, could cause actual results to differ materially including changes related to regulatory and environmental approvals, manufacturing, operations, capital needs, technological advances by competitors and changes in health care reform, including reimbursement programs.

Certain information concerning economic trends and performance is based upon or derived from information provided by third-party consultants and other industry sources. While the Company believes that such information is accurate and that the sources from which it was obtained are reliable, it cannot guarantee the accuracy of such information, as it has not independently verified the assumptions on which projections of future trends and performance are based.

Retains Barry Kaplan Associates for Investor Relations